FI20050695A0 - Menetelmä fosfolipidi-PEG-biomolekyyli-konjugaattien valmistamiseksi - Google Patents

Menetelmä fosfolipidi-PEG-biomolekyyli-konjugaattien valmistamiseksi

Info

Publication number
FI20050695A0
FI20050695A0 FI20050695A FI20050695A FI20050695A0 FI 20050695 A0 FI20050695 A0 FI 20050695A0 FI 20050695 A FI20050695 A FI 20050695A FI 20050695 A FI20050695 A FI 20050695A FI 20050695 A0 FI20050695 A0 FI 20050695A0
Authority
FI
Finland
Prior art keywords
phospholipid
peg
preparation
biomolecule conjugates
biomolecule
Prior art date
Application number
FI20050695A
Other languages
English (en)
Swedish (sv)
Original Assignee
Ctt Cancer Targeting Tech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctt Cancer Targeting Tech Oy filed Critical Ctt Cancer Targeting Tech Oy
Priority to FI20050695A priority Critical patent/FI20050695A0/fi
Publication of FI20050695A0 publication Critical patent/FI20050695A0/fi
Priority to US11/443,338 priority patent/US20070004631A1/en
Priority to EP06397013A priority patent/EP1738770A1/en
Priority to JP2006172880A priority patent/JP2007008933A/ja
Priority to CA002551437A priority patent/CA2551437A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
FI20050695A 2005-06-30 2005-06-30 Menetelmä fosfolipidi-PEG-biomolekyyli-konjugaattien valmistamiseksi FI20050695A0 (fi)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FI20050695A FI20050695A0 (fi) 2005-06-30 2005-06-30 Menetelmä fosfolipidi-PEG-biomolekyyli-konjugaattien valmistamiseksi
US11/443,338 US20070004631A1 (en) 2005-06-30 2006-05-31 Method for synthesis of phospholipids-PEG-biomolecule conjugates
EP06397013A EP1738770A1 (en) 2005-06-30 2006-06-13 Method for synthesis of phospholipids-PEG-biomolecule conjugates
JP2006172880A JP2007008933A (ja) 2005-06-30 2006-06-22 リン脂質−ｐｅｇ−生体分子コンジュゲートの合成法
CA002551437A CA2551437A1 (en) 2005-06-30 2006-06-28 Method for synthesis of phospholipids-peg-biomolecule conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20050695A FI20050695A0 (fi) 2005-06-30 2005-06-30 Menetelmä fosfolipidi-PEG-biomolekyyli-konjugaattien valmistamiseksi

Publications (1)

Publication Number Publication Date
FI20050695A0 true FI20050695A0 (fi) 2005-06-30

Family

ID=34778405

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20050695A FI20050695A0 (fi) 2005-06-30 2005-06-30 Menetelmä fosfolipidi-PEG-biomolekyyli-konjugaattien valmistamiseksi

Country Status (5)

Country Link
US (1) US20070004631A1 (fi)
EP (1) EP1738770A1 (fi)
JP (1) JP2007008933A (fi)
CA (1) CA2551437A1 (fi)
FI (1) FI20050695A0 (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1935433A1 (en) * 2006-12-13 2008-06-25 Institute of Nuclear Energy Research, Atomic Energy Council A method for preparing covalent lipid-spacer-peptide conjugates
EP2606911A1 (en) * 2007-02-16 2013-06-26 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
WO2009128789A1 (en) * 2008-04-17 2009-10-22 Agency For Science, Technology And Research Vesicles for intracellular drug delivery
EP3897736B1 (en) 2018-12-18 2022-10-12 Bracco Suisse SA Optimized process for dimeric peptide-phospholipid conjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01100150A (ja) * 1987-10-13 1989-04-18 Mitsui Petrochem Ind Ltd 芳香族アミンの製造方法
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AU2002225878A1 (en) * 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi

Also Published As

Publication number Publication date
EP1738770A1 (en) 2007-01-03
JP2007008933A (ja) 2007-01-18
US20070004631A1 (en) 2007-01-04
CA2551437A1 (en) 2006-12-30

Similar Documents

Publication Publication Date Title
FI20055616A0 (fi) Menetelmä valmisteen rakenteen muokkaamiseen
DK1912671T3 (da) Beta-glucuronid-linker-lægemiddelkonjugater
NO20076607L (no) TWEAK - bindende antistoff
DK1964852T3 (da) Anti-ilt7-antistof
DK1853310T3 (da) Anti-Abeta-antistofpræparat
DE602006002527D1 (de) Versiegelungsvorrichtung
DK2047098T3 (da) Kalibreringsfremgangsmåde
FI20055661A0 (fi) Prosessi tyydyttyneen hiilivetykomponentin valmistamiseksi
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
DE602006006395D1 (de) Versiegelungsgerät
FI20055665A0 (fi) Prosessi haarautuneen hiilivetykomponentin valmistamiseksi
GB0517487D0 (en) Antibodies
DE602006020716D1 (de) Kastenloses formverfahren
IL190666A0 (en) Process for the preparation of insulin conjugates
DE602006012689D1 (de) Überprüfungsverfahren
BRPI0819765A2 (pt) Conjugados de anticorpos anti-rg-1
FI20055666A0 (fi) Prosessi hiilivetykomponentin valmistamiseksi
FI20065860A0 (fi) Menetelmä mekaanisen massan valmistamiseksi
DE602006014973D1 (de) Neuartige cercosporamidderivate
FI20050554A (fi) Menetelmä etanoli-vesiseoksen valmistamiseksi
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
FI20050695A0 (fi) Menetelmä fosfolipidi-PEG-biomolekyyli-konjugaattien valmistamiseksi
FI20050577A0 (fi) Menetelmä adamantaanijohdannaisten valmistamiseksi
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES

Legal Events

Date Code Title Description
FD Application lapsed